ETOP 25-23 ADOPT-lung: An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC
Publication date
2025-08
Authors
Schmid, Sabine
Dimopoulou, Georgia
van Schil, Paul
König, David
Mauti, Laetitia
Itchins, Malinda
Früh, Martin
Oselin, Kersti
Landi, Lorenza
Pérol, Maurice
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
cc_by
Abstract
Keywords
Journal Article
Citation
Schmid, S, Dimopoulou, G, van Schil, P, König, D, Mauti, L, Itchins, M, Früh, M, Oselin, K, Landi, L, Pérol, M, Popat, S, Aigner, C, Forde, P, de Jong, W K, Roschitzki-Voser, H, Grolimund, E, Ruepp, B, Solomon, B, Finn, S, Dafni, U, Stahel, R, Peters, S & ETOP 25-23 ADOPT-lung collaborators 2025, 'ETOP 25-23 ADOPT-lung : An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC', Lung Cancer, vol. 206, 108635. https://doi.org/10.1016/j.lungcan.2025.108635